Drug intelligence / Profile preview

AMT-210

Development stage: Discontinued
Lead developer: uniQure
Modality: Gene Therapies

Overview

AMT-210 is an investigational **AAV-based gene therapy** from **uniQure** that was being developed for **Parkinson's disease**. Publicly available pipeline descriptions indicate it was a **one-time gene transfer program** intended to reduce **misfolded alpha-synuclein** in the brain, consistent with a gene-silencing strategy directed at **alpha-synuclein** biology. The program appears to have remained **preclinical** and, based on company restructuring disclosures in 2023, development for Parkinson's disease was **terminated or no longer pursued before entry into the clinic**.

Targets

Alpha-synuclein messenger RNA

Beyond the preview

Go deeper on AMT-210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMT-210.

Explore the full profile